



# Biotech Daily

Friday November 7, 2008

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECHS DOWN: GENETIC TECHNO UP 40%, CYTOPIA DOWN 21%**
- \* **BIOTECH DAILY IS THREE**
- \* **DIVISION AT LIVING CELL AGM**
- \* **OCCUPATIONAL & MEDICAL RAISES \$503k**
- \* **BIO-MELBOURNE REMINDER: STRATEGIC COMMUNICATIONS**

## MARKET REPORT

The Australian stock market fell 2.4 percent on Friday November 7, 2008 with the All Ordinaries down 99.9 points to 4,006.6 points.

Six of the Biotech Daily Top 40 stocks were up, 18 fell, 10 traded unchanged and six were untraded.

Genetic Technologies was best for the second day in a row, up 2.4 cents or 40.0 percent to 8.4 cents with 99,811 shares traded, followed by Alchemia up three cents or 16.67 percent to 21 cents and Phosphagenics up one cent or 13.33 percent to 8.5 cents. Phylogica climbed 9.09 percent; Antisense was up 8.89 percent; with Impedimed up 2.08 percent.

Cytopia led the falls, down four cents or 21.05 percent to 15 cents with 9,260 shares traded, followed by Novogen down 17.5 cents or 19.23 percent to 73.5 cents and Polartechnics down 10.0 percent to 8.1 cents.

Sirtex lost 7.83 percent; Acrux fell 5.88 percent; Benitec, Mesoblast and Ventracor fell more than four percent; Peplin, Resmed, Universal Biosensors and Viralytics were down more than three percent; Arana, Cellestis, Chemgenex, Living Cell and Optiscan shed more than two percent; with Pharmaxis and Psivida down one percent or more.

## BIOTECH DAILY

Biotech Daily is three years old today and with more than 720 editions under our belt we have begun to learn a little about listed biotechnology and medical technology companies.

We would like to thank every subscriber for having the investment faith to part with funds to create the publication and to keep it going.

While maintaining a straight 'vanilla' industry publication, Biotech Daily has introduced Marc Sinatra's Bio-Guides, CEO Interviews and recently created an informal but confidential employment service.

In 2009 we intend to create a user-friendly searchable library.

For those not able to attend tonight's 3<sup>rd</sup> Birthday celebration, thank you for your generous support.

David Langsam  
Editor

## LIVING CELL TECHNOLOGIES

Despite a very good year for Living Cell a large minority of shareholders have opposed all annual general meeting resolutions except the reelection of founder David Collinson. Living Cell has had positive results from its Russian xenotransplant Type 1 Diabetes trial and last month received New Zealand approval for the first Western world xenotransplant trial of porcine islets of Langerhans to treat Type 1 diabetes (see Biotech Daily October 28, 2008).

The remuneration report was opposed by 13,649,118 proxy votes with 31,448,111 proxy votes in favor.

The resolution to issue options to chief executive officer Dr Robert Caspari was similarly divided.

The reelection of director Simon O'Loughlin was opposed by 25,810,891 proxy votes, while Mr Collinson was reelected with 45,158,779 votes in favor and no proxy votes against.

Only the reelection of Mr O'Loughlin was opposed on a show of hands in the meeting, with the other three resolutions carried unanimously on a show of hands.

Living Cell fell half a cent or 2.63 percent to 18.5 cents.

## OCCUPATIONAL & MEDICAL INNOVATIONS

Occupational & Medical Innovations has raised \$503,250 in "a limited placement" to sophisticated investors within the current shareholder base.

Occupational & Medical said expressions of interest were sought from those sophisticated shareholders to buy new shares at 25 cents a share, with a view to raising \$500,000.

The company said that at November 4, 2008 it had received acceptances for a total of \$503,250 for 2,013,000 shares and the offer has been closed.

Occupational & Medical was untraded at 37 cents.

## BIO-MELBOURNE NETWORK

Bio-Melbourne Network will hold a workshop on strategic communications for biotechnology managers on November 13, 2008.

The Bio-Melbourne Network says that with biotech investment market windows narrowing and private capital very nervous about risk profiles, "it is vitally important for biotech companies to implement well-planned communication strategies for investors, shareholders and collaboration partners".

The Network says its November workshop "looks at building on effective communications strategy as a driver of corporate value and risk management" and says the session will approach this requirement from communication strategy, issues management, analyst and investor relations, as well as a media relations perspectives.

Attendees will be provided with a strategic communications and issues management template and will have an opportunity to use this tool to directly apply to their organizations. Electronic copies will be provided.

Bio-Melbourne Network chief executive officer, Michelle Gallaher, will introduce the workshop and present on communications strategic planning, including handling the hard issues.

Prior to joining the Bio-Melbourne Network, Ms Gallaher was public affairs director at the Australia Stem Cell Centre.

Ms Gallaher will examine communications plans; integration of issues management planning into the organizational risk plan; identification of issues before they break with stakeholders; target audiences including audience segmentation and hierarchy; timing; legal issues in an emerging crisis; communications strategies in litigation or defence; post event strategies for investors, staff, collaborators and the annual general meeting.

Seed Media director, Andrew Geddes, will present on strategies for communicating with the market and investors.

Prior to starting his own consultancy Mr Geddes was investor relations manager with Ventracor.

He will discuss developing a relationship and credibility; what analysts and investors want to know and how to talk to them; clear communication and announcement valuations; honesty in communications; and timing.

Media Manoeuvres chief executive officer Sam Elam will present on media relations strategies.

Ms Elam will cover how the media works; the key drivers of stories and deadlines; different media, different rules; building credibility; building a relationship; the media release; and the need to make sure someone is available who knows their subject matter.

The workshop will conclude with a 30 minute panel discussion to answer questions and gather the experiences of the attendees to round out the morning's discussion.

The workshop will be held in the Supper Room, Melbourne Town Hall, Swanston St, Melbourne with registration from 8.45am.

The workshop starts at 9am and will be followed by a light luncheon.